<DOC>
	<DOCNO>NCT00699179</DOCNO>
	<brief_summary>This study conduct Europe . This observational study aim reflect post-authorisation experience insulin analogue ( biphasic insulin aspart 30 ) use normal clinical practice condition Serbia .</brief_summary>
	<brief_title>Observational Study Evaluate Efficacy Safety NovoMixÂ® 30 Type 1 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 Type 2 Diabetes Mellitus inadequately control human insulin therapy last least 6 month HbA1c great 7 % Informed Consent Patients hypersensitivity biphasic insulin aspart 30 excipients Other limit condition specify locally approve NovoMix 30 SPC ( Summary Product Characteristics ) , PIL ( Patient Information Leaflet ) . Women pregnant , breast feeding intention become pregnant within next couple month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>